Skip to main content
. 2014 Apr 28;6:47–54. doi: 10.2147/DHPS.S43275

Figure 3.

Figure 3

Primary composite end point (hospitalization for worsening heart failure or cardiovascular death) in SHIFT.

Note: Reprinted from The Lancet, 376(9744), Swedberg K, Komajda M, Böhm M, et al., Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. 875–885, Copyright 2010, with permission from Elsevier.4

Abbreviation: SHIFT, Systolic heart failure treatment with the If inhibitor ivabradine trial.